Sean Brynjelsen - Jan 3, 2025 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
President & CEO, Director
Signature
/s/ James R. Gruber
Stock symbol
ETON
Transactions as of
Jan 3, 2025
Transactions value $
$0
Form type
4
Date filed
1/6/2025, 04:18 PM
Previous filing
Feb 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Employee Stock Option (Right to Buy) Award $0 +107K $0.00 107K Jan 3, 2025 Common Stock 107K $13.00 Direct F1
transaction ETON Restricted Stock Units Award $0 +72K $0.00 72K Jan 3, 2025 Common Stock 72K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029.
F2 Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
F3 The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.